In a regulatory filing, Xenon Pharmaceuticals director Dawn Svoronos disclosed the sale of 25,000 common shares of the company on August 24 at a price of $38.70 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XENE:
- Xenon Pharmaceuticals reports Q2 EPS (72c), consensus (70c)
- Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
- Xenon Pharmaceuticals (XENE) Q2 Earnings Cheat Sheet
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update